CRISPR and Fanzor in sickle cell disease: current progress and future prospects

Area of Science:

• Genetics and Genomics
• Molecular Biology
• Biotechnology

Background:

• Sickle cell disease (SCD) is a prevalent monogenic blood disorder causing significant morbidity and mortality.
• CRISPR-Cas9 gene therapy represents a breakthrough for SCD treatment, with recent clinical approvals.
• Existing CRISPR technology faces limitations necessitating exploration of alternative genome editing tools.

Purpose of the Study:

• To review the successes and limitations of CRISPR-Cas9 for SCD mutation editing.
• To explore the potential of the Fanzor (Fz) system as a novel genome editing tool for SCD.
• To compare the characteristics of CRISPR and Fz systems for therapeutic applications.

Main Methods:

• Literature review of CRISPR-Cas9 applications in SCD.
• Comparative analysis of CRISPR-Cas9 and Fanzor system mechanisms and origins.
• Exploration of Fanzor system's potential in eukaryotic gene editing for SCD.

Main Results:

• CRISPR-Cas9 has achieved significant milestones in treating severe sickle cell anemia.
• Limitations in CRISPR technology, such as delivery and off-target effects, persist.
• The Fanzor system, encoded in eukaryotes, offers a universal RNA-guided mechanism with potential for enhanced delivery.

Conclusions:

• CRISPR-Cas9 is a powerful tool for SCD gene therapy, but ongoing innovation is crucial.
• The Fanzor system holds promise as a complementary or alternative genome editing tool for SCD.
• Further research is needed to evaluate the Fanzor system's efficacy and safety for SCD treatment.